Composition for preventing or treating cancer comprising phenaleno isoquinolinium-based derivative as active ingredient
The fenalenoisoquinolinium derivative composition addresses the limitations of existing theranostic agents by inducing apoptosis in cancer cells and providing effective cancer diagnosis and treatment with enhanced biocompatibility and delivery, as evidenced by its strong fluorescent properties and selective cytotoxicity.
Patent Information
- Application Number
- PCT/KR2024/006644
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-21
AI Technical Summary
Current theranostic agents for cancer diagnosis and treatment face challenges such as difficulty in preparation, inefficient delivery, and low therapeutic effect due to their large size and intrinsic structure, limiting their effectiveness in targeting and treating cancer cells.
A composition containing a fenalenoisoquinolinium derivative as an active ingredient, which induces rapid apoptosis of cancer cells through the p53, p21, or caspase-3 signaling pathway, and exhibits strong fluorescent properties for simultaneous diagnosis and treatment, enhancing biocompatibility and delivery to cancer cells.
The fenalenoisoquinolinium derivative composition effectively targets and treats cancer cells, demonstrating high sensitivity and delivery ability, enabling accurate diagnosis and effective treatment with minimal impact on normal cells, as shown by in vitro and in vivo fluorescence imaging and cytotoxicity studies.
Smart Images

Figure KR2024006644_21112024_PF_FP_ABST
Abstract
Description
Composition for preventing or treating cancer comprising a phenaleno isoquinolinium derivative as an active ingredient
[0001] The present invention relates to a composition for preventing or treating cancer comprising a phenaleno isoquinolinium derivative as an active ingredient.
[0002] Cancer is the most life-threatening disease in human history. As cancer cells grow and proliferate, they form tumors, massive tumors that invade and destroy surrounding healthy cells. While cancer treatment technologies have continuously advanced, existing treatments, such as surgery, radiation therapy, and chemotherapy, only treat early-stage cancer, have a high risk of recurrence, and have various side effects, such as destroying normal cells in addition to cancer cells. Therefore, new treatments and drugs for effective cancer treatment are urgently needed.
[0003] Theragnosis is a therapeutic technology that simultaneously performs diagnosis and treatment, and numerous theranostic agents that enable this have been developed over the years. These can be classified into two types: multifunctional complexes consisting of therapeutic agents and imaging units in various nanoparticles, polymers, and protein conjugates; and macromolecules, which combine various functional components such as drugs, imaging units, targeting moieties, and quenchers. These agents exhibit excellent solubility and biocompatibility and are easily distributed to target lesions, enabling accurate diagnosis and effective treatment. However, their inherent structure and large size present challenges, including difficulties in preparation, inefficient delivery, and low therapeutic efficacy.
[0004] Sentinel lymph nodes (SLNs) are crucial for monitoring cancer metastasis. They are the first lymph nodes to which lymph fluid draining from the primary tumor reaches. Monitoring sentinel lymph nodes can be used to assess the potential for tumor metastasis. This process, known as SLN mapping, involves injecting lymph node dye into cancerous tissue and using various molecular imaging techniques to identify surrounding lymph nodes. These nodes are then resected and biopsied to confirm the presence of lymph node metastasis and diagnose metastatic cancer. If SLN biopsy reveals no metastasis, other lymph nodes can be left untreated and observed, reducing the risk of complications and economic costs associated with unnecessary surgery. SLN mapping is currently the standard diagnostic method for early-stage breast cancer and epithelial melanoma, and active research is underway to explore its clinical applicability to other cancers, including colorectal, gastric, lung, esophageal, and oral cancers.
[0005] Molecular imaging techniques are used to precisely locate lymph nodes surrounding tumors, and near-infrared (NIR) fluorescent dyes are emerging as ideal building blocks for theranostic platform development due to their low toxicity and unique optical properties. Therefore, the inventors of the present invention sought to develop a fluorescent dye capable of simultaneous diagnosis and treatment. They discovered that phenalenoic isoquinolinium derivative compounds enable both cancer diagnosis and treatment, and completed the present invention.
[0006] The present invention was devised to solve the problems of conventional theragnosis preparations, and aims to provide a composition for preventing or treating cancer that has high biocompatibility and excellent sensitivity, and excellent target delivery ability, thereby effectively treating cancer.
[0007] In order to achieve the above purpose, the present invention provides a composition for preventing or treating cancer, which comprises a compound represented by the following chemical formula 1 as an active ingredient.
[0008] Chemical Formula 1
[0009]
[0010] {In the above chemical formula 1,
[0011] R 1 Silver substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C7~C 20 is selected from the group consisting of arylalkyl groups;
[0012] R 2 are each identical, substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C2~C 20 is selected from the group consisting of heterocyclic groups;
[0013] X - is an inorganic acid ion, an organic acid ion, or a halide,
[0014] Here, the alkyl group, alkenyl group, arylalkyl group, aryl group and heterocyclic group are deuterium; halogen; C1~C 10 Alkyl group of; C1~C 10 Alkoxy group of; C6~C 20 aryl group of; and -NR'R"; may be further substituted with one or more substituents selected from the group consisting of
[0015] The above R' and R" are independently C1~C 10 is selected from the group consisting of an alkyl group; a phenyl group; and a halogenated phenyl group.
[0016] In addition, the present invention provides the R 1 C1~C substituted with silver halogen 20 Provided is a composition for preventing or treating cancer, which is an alkyl group.
[0017] In addition, the present invention provides the R 2 Provides a composition for preventing or treating cancer, wherein the R is a substituted or unsubstituted phenyl group, more preferably 2 Provides a composition for preventing or treating cancer, which is a phenyl group.
[0018] In addition, the present invention provides the R 2 is C1~C 20 Provided is a composition for preventing or treating cancer, which is an alkyl group.
[0019] In addition, the present invention provides the R 2 is substituted or unsubstituted C2~C 20 A composition for preventing or treating cancer is provided, which is a heterocyclic group.
[0020] In addition, the present invention provides the R 2 Provided is a composition for preventing or treating cancer, wherein the composition is a phenyl group substituted with one or more substituents selected from the group consisting of halogen, a C1-C6 alkoxy group and -NR'R", wherein R' and R" are each independently a C1-C6 alkyl group or a phenyl group.
[0021] The above composition is characterized by inducing rapid apoptosis of cancer cells through the p53, p21 or caspase-3 signaling pathway.
[0022] The above cancers include brain cancer, neuroendocrine cancer, myeloma, lymphoma, leukemia, lymphangioendotheliosarcoma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, glioma, meningioma, neuroblastoma, EMC (extraskeletal myxoid chondrosarcoma), stomach cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, adrenal cancer, colon cancer, colon cancer, cervical cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, parathyroid cancer, ureter cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, colon adenocarcinoma, prostate carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma. It may include hepatocellular carcinoma, biliary tract cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, hemangiosarcoma, endotheliosarcoma, lymphangiosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, rhabdomyoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, bulbar thyroid carcinoma, bronchial carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, Kaposi's sarcoma, or retinoblastoma.
[0023] In addition, in another aspect, the present invention provides a composition for near-infrared treatment of cancer comprising a compound represented by the above chemical formula 1 as an active ingredient.
[0024] In addition, in another aspect, the present invention provides a composition for preventing or treating cancer metastasis, comprising a compound represented by the above chemical formula 1 as an active ingredient.
[0025] In another aspect, the present invention provides a method of treating cancer in a non-human animal comprising administering the composition.
[0026] The composition for preventing or treating cancer according to the present invention can simultaneously diagnose and treat cancer by emitting a strong fluorescent signal as a theranostic agent and exhibiting antitumor activity.
[0027] Figures 1a and 1b illustrate an in vitro fluorescence intensity analysis image (1a) and a fluorescence signal quantification graph (1b) of a tube containing a compound according to one embodiment of the present invention.
[0028] Figures 2a to 2d show the results of cell viability analysis in normal cells and colon cancer cells treated with compounds MF19 (2a), MF32 (2b), MF33 (2c), and MF44 (2d) according to one embodiment of the present invention.
[0029] Figure 2e shows the results of cell viability analysis in lung cancer, prostate cancer, and thyroid cancer cells treated with compound MF33 according to one embodiment of the present invention.
[0030] Figure 2f shows images of colony formation assays in HCT-116 cells treated with vehicle or MF33.
[0031] Figure 2g shows the results of apoptosis analysis of HCT-116 cells treated with compound MF33 according to one embodiment of the present invention.
[0032] Figures 3a to 3g illustrate the results of analyzing the effect of MF33 on the apoptotic signal transduction pathway according to one embodiment of the present invention. Western blot (3a) showing changes in protein expression in MF33-treated HCT-116 cells, and results of quantitative protein level analysis (3b to 3g).
[0033] Figures 4a to 4d illustrate the results of in vivo fluorescence imaging analysis of MF33 biodistribution after intravenous injection according to one embodiment of the present invention. In vivo imaging analysis results of MF33-injected mice (4a), fluorescence signal quantification graph (4b), ex vivo imaging analysis results of resected organs (4c), fluorescence signal quantification graph of resected organs (4d).
[0034] Figures 5a to 5f illustrate the results of in vivo visualization of tumor lesions in HCT-116 tumor-bearing mice using MF33 according to one embodiment of the present invention. Results of cellular uptake of MF33 in normal colon cells CCD18Co (5a), colon cancer cells RKO (5b), and colon cancer cells HCT-116 (5c), results of in vivo imaging analysis of HCT-116 tumor-bearing mice (5d), results of ex vivo imaging analysis of resected tumors (5e), and graph of quantification of fluorescent signals in resected tumors (5f).
[0035] Figures 6a to 6c show the results of in vivo imaging analysis of sentinel lymph nodes using MF33 according to one embodiment of the present invention (6a), the results of ex vivo imaging analysis of resected sentinel lymph nodes (6b), and the results of ex vivo imaging analysis of resected feet (6c).
[0036] Figures 7a to 7d show the results of an antitumor activity assay of MF33 in HCT-116 tumor-bearing mice according to one embodiment of the present invention. Tumor volume (7a), tumor volume 18 days after treatment (7b), body weight measurement (7c), and weight of resected tumor (7d).
[0037] Hereinafter, the present invention will be described in detail with reference to embodiments. In describing the present invention, if a detailed description of a related known configuration or function is judged to obscure the gist of the present invention, such detailed description will be omitted.
[0038] As used in this specification and the appended claims, unless otherwise stated, the following terms have the following meanings:
[0039] As used herein, "alkyl group" means a straight-chain or branched-chain, or cyclic hydrocarbon radical, or a combination thereof, which may be fully saturated, partially or fully unsaturated, and having the specified number of carbon atoms (e.g., C1 to C 20) may contain divalent and multivalent radicals.
[0040] As used herein, “alkenyl group” means a carbon chain having a carbon-carbon double bond.
[0041] As used herein, “aryl group” means a monocyclic or polycyclic aromatic group containing carbon atoms and hydrogen atoms.
[0042] In this specification, “arylalkyl group” means an alkyl group substituted with an aryl group.
[0043] As used herein, “heterocyclic group” means a monocyclic or polycyclic ring containing one or more heteroatoms, and may be alicyclic and / or aromatic.
[0044] As used herein, “halide” means a halogen such as fluorine, chlorine, bromine and iodine.
[0045]
[0046] Hereinafter, a composition for preventing or treating cancer comprising a phenaleno isoquinolinium derivative according to one aspect of the present invention as an active ingredient will be described.
[0047] The present invention provides a composition for preventing or treating cancer, which comprises a phenaleno isoquinolinium compound represented by the following chemical formula 1 as an active ingredient.
[0048] Chemical Formula 1
[0049]
[0050] {In the above chemical formula 1,
[0051] R 1 Silver substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C7~C 20 is selected from the group consisting of arylalkyl groups;
[0052] R 2 are each identical, substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C2~C 20 is selected from the group consisting of heterocyclic groups;
[0053] X - is an inorganic acid ion, an organic acid ion, or a halide,
[0054] Here, the alkyl group, alkenyl group, arylalkyl group, aryl group and heterocyclic group are deuterium; halogen; C1~C 10 Alkyl group of; C1~C 10 Alkoxy group of; C6~C 20 aryl group of; and -NR'R"; may be further substituted with one or more substituents selected from the group consisting of
[0055] The above R' and R" are independently C1~C 10 is selected from the group consisting of an alkyl group; a phenyl group; and a halogenated phenyl group.
[0056]
[0057] In addition, the present invention provides the R 1 C1~C substituted with silver halogen 20 Provided is a composition for preventing or treating cancer, which is an alkyl group.
[0058] In addition, the present invention provides the R 2 Provides a composition for preventing or treating cancer, which is a substituted or unsubstituted phenyl group. Preferably, the R 2 is a phenyl group; or a phenyl group substituted with one or more substituents selected from the group consisting of a halogen, a C1-C6 alkoxy group and -NR'R"; wherein, it is preferable that R' and R" are each independently a C1-C6 alkyl group or a phenyl group.
[0059] In addition, the present invention provides the R 2 is C1~C 20 Provided is a composition for preventing or treating cancer, which is an alkyl group.
[0060] In addition, the present invention provides the R 2 is substituted or unsubstituted C2~C 20 A composition for preventing or treating cancer is provided, which is a heterocyclic group.
[0061]
[0062] As an example, the present invention provides a composition for preventing or treating cancer, wherein the compound represented by the above chemical formula 1 comprises a compound represented by the following chemical formula 2.
[0063] Chemical Formula 2
[0064]
[0065] {In the above chemical formula 2, R 2 and X - is the same as defined in the above chemical formula 1.
[0066]
[0067] In addition, as an example, the present invention provides a composition for preventing or treating cancer, wherein the compound represented by the above chemical formula 1 comprises a compound represented by any one of the following compounds.
[0068]
[0069]
[0070] {In the above compound, X - is the same as defined in the above chemical formula 1.
[0071]
[0072] The composition can induce apoptosis of cancer cells by promoting cleavage of poly(ADP-ribose) polymerase (PARP), caspase-3, caspase-8, or caspase-9.
[0073] The above composition can induce rapid apoptosis of cancer cells through the p53, p21 or caspase-3 signaling pathway.
[0074] The above cancers include brain cancer, neuroendocrine cancer, myeloma, lymphoma, leukemia, lymphangioendotheliosarcoma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, glioma, meningioma, neuroblastoma, EMC (extraskeletal myxoid chondrosarcoma), stomach cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, adrenal cancer, colon cancer, colon cancer, cervical cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, parathyroid cancer, ureter cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, colon adenocarcinoma, prostate carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma. These may include, but are not limited to, hepatocellular carcinoma, biliary tract cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, hemangiosarcoma, endotheliosarcoma, lymphangiosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, rhabdomyoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, bulbar thyroid carcinoma, bronchial carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, Kaposi sarcoma, or retinoblastoma.
[0075]
[0076] In addition, in another aspect, the present invention provides a composition for near-infrared treatment of cancer, comprising a compound represented by the following chemical formula 1 as an active ingredient.
[0077] Chemical Formula 1
[0078]
[0079] {In the above chemical formula 1,
[0080] R 1 Silver substituted or unsubstituted C1~C20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C7~C 20 is selected from the group consisting of arylalkyl groups;
[0081] R 2 are each identical, substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C2~C 20 is selected from the group consisting of heterocyclic groups;
[0082] X - is an inorganic acid ion, an organic acid ion, or a halide,
[0083] Here, the alkyl group, alkenyl group, arylalkyl group, aryl group and heterocyclic group are deuterium; halogen; C1~C 10 Alkyl group of; C1~C 10 Alkoxy group of; C6~C 20 aryl group of; and -NR'R"; may be further substituted with one or more substituents selected from the group consisting of
[0084] The above R' and R" are independently C1~C 10 is selected from the group consisting of an alkyl group; a phenyl group; and a halogenated phenyl group.
[0085]
[0086] In addition, in another aspect, the present invention provides a composition for preventing or treating cancer metastasis, comprising a compound represented by the following chemical formula 1 as an active ingredient.
[0087] Chemical Formula 1
[0088]
[0089] {In the above chemical formula 1,
[0090] R 1Silver substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C7~C 20 is selected from the group consisting of arylalkyl groups;
[0091] R 2 are each identical, substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C2~C 20 is selected from the group consisting of heterocyclic groups;
[0092] X - is an inorganic acid ion, an organic acid ion, or a halide,
[0093] Here, the alkyl group, alkenyl group, arylalkyl group, aryl group and heterocyclic group are deuterium; halogen; C1~C 10 Alkyl group of; C1~C 10 Alkoxy group of; C6~C 20 aryl group of; and -NR'R"; may be further substituted with one or more substituents selected from the group consisting of
[0094] The above R' and R" are independently C1~C 10 is selected from the group consisting of an alkyl group; a phenyl group; and a halogenated phenyl group.
[0095]
[0096] In another aspect, the present invention provides a method of treating cancer in a non-human animal comprising administering the composition.
[0097]
[0098] In addition, in the present invention, the composition may include a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient in addition to the phenaleno isoquinolinium compound. Specifically, the carrier is one commonly used in formulations, and may be, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil. Excipients such as cocoa butter and suppository wax, coloring agents, coating agents, sweeteners, flavoring agents, and fragrances may also be present in the composition.
[0099] The excipients include any and all solvents, inert diluents, dispersing and / or granulating agents, surface active and / or emulsifying agents, disintegrating agents, binders, preservatives, buffers, lubricants and / or oils suitable for the particular dosage form desired. Excipients such as cocoa butter and suppository wax, coloring agents, coating agents, sweetening agents, flavoring agents and perfuming agents may also be present in the composition.
[0100] Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and combinations thereof.
[0101] Exemplary preservatives include, but are not limited to, antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acid preservatives, and other preservatives.
[0102] Exemplary antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium iodide, sodium metabisulfite, sodium nitrite, sodium sulfite, and sodium thiosulfate.
[0103] Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and its salts and hydrates (e.g., sodium edetate, disodium edetate, trisodium edetate, disodium calcium edetate, dipotassium edetate, etc.), citric acid and its salts and hydrates (e.g., citric acid monohydrate), fumaric acid and its salts and hydrates, malic acid and its salts and hydrates, phosphoric acid and its salts and hydrates, and tartaric acid and its salts and hydrates. Exemplary antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
[0104] Exemplary antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
[0105] Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenols, chlorobutanol, hydroxybenzoates, and phenylethyl alcohol.
[0106] Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
[0107] Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, and Euxyl.
[0108] Exemplary buffers include citrate buffer solution, acetate buffer solution, phosphate buffer solution, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium globionate, calcium glucept, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide, potassium acetate, potassium chloride, potassium gluconate, potassium mixture, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixture, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixture, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and the like, and combinations thereof, are included but are not limited thereto.
[0109] The composition of the present invention may be administered orally or parenterally. In the case of parenteral administration, it may be administered parenterally by intravenous injection, intraarterial injection, subcutaneous injection, intramuscular injection, intra-articular injection, intrasynovial injection, intrathecal injection, intrahepatic injection, intralesional injection, intracranial injection, or topically. Specifically, the composition of the present invention may be formulated as an injection and administered intravenously, but is not limited thereto.
[0110] In addition, the composition may take various forms, including, but not limited to, a liquid, suspension, paste, powder, concentrate, granulated powder for mixing to an appropriate concentration, or a solid form, each according to a conventional method. For example, the composition of the present invention may be prepared in the form of an injection, a preparation for transdermal administration, a preparation for intubation, a preparation for oral administration, or a preparation for rectal administration.
[0111] The appropriate dosage of the composition of the present invention can be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity.
[0112]
[0113] The composition according to the present invention can visualize a target by absorbing light in the near-infrared wavelength range at the target and fluorescing to increase the fluorescence signal, thereby enabling the exploration of sentinel lymph nodes (SLNs) or the diagnosis of cancer or cancer metastasis through fluorescence imaging, and simultaneously performing cancer treatment, and thus can be used as a theragnosis composition.
[0114]
[0115] Hereinafter, examples of synthesis and examples of the compound represented by the chemical formula 1 of the present invention will be described in detail with reference to examples, but the present invention is not limited to the following examples.
[0116] <Reaction Scheme 1>
[0117]
[0118] As shown in the above reaction scheme 1, the compound according to the present invention can be prepared through a simple one-step N-annulation reaction under a Rh(III) catalyst.
[0119]
[0120] In addition, the compound represented by chemical formula 2 according to the present invention can be prepared by a reaction as in the following reaction formula 2, but is not limited thereto.
[0121] <Reaction Formula 2>
[0122]
[0123]
[0124] I. Sub 1 Synthesis Example
[0125] 1. Synthesis example of 1a (3-chloro-N-(pyren-1-ylmethyl)propan-1-amine; 3-chloro-N-(pyren-1-ylmethyl)propan-1-amine)
[0126] 1-Pyrene aldehyde (4.34 mmol, 1 g), 3-chloropropan-1-amine hydrochloride (4.34 mmol, 0.565 g), TEA (2.42 mL), and methanol (6.5 mL) were added to a 25 mL round-bottomed flask, stirred and refluxed for 24 hours, cooled to 0℃, added sodium borohydride (13 mmol, 0.5 g), and stirred for 24 hours. When the reaction was complete, water was slowly added and washed three times with dichloromethane. The organic layer was dried over anhydrous Na2SO4, filtered under reduced pressure, concentrated, and purified by column chromatography (n-hexane:ethyl acetate = 5:1) to obtain the product (white solid, yield 46%, 0.61 g).
[0127] 1 H NMR (400 MHz, CDCl3) δ 8.37 (d,J= 9.24 Hz, 1H), 8.20-8.17 (m, 2H), 8.14 (d,J= 8.32 Hz, 2H), 8.04 (s, 2H), 8.02-7.98 (m, 2H), 4.49 (s, 2H), 3.67 (t,J= 6.48 Hz, 2H), 2.96 (t,J= 6.72 Hz, 2H), 2.02 (quint,J= 6.56 Hz, 2H), 1.50 (br-s, 1H); 13 C NMR (100 MHz, CDCl3) δ 133.9, 131.5, 131.0, 130.9, 129.3, 127.8, 127.6, 127.3, 127.2, 126.1, 125.3, 125.2, 125.0, 124.9, 123.4, 52.2, 47.0, 43.4, 33.1.
[0128]
[0129] II. Chemical Formula 1 Synthesis Example
[0130] 1. Synthesis example of MF19 (9-(3-chloropropyl)-7,8-diphenylphenaleno[1,9-gh]isoquinolin-9-ium tetrafluoroborate)
[0131] A 5 mL vial was charged with 3-chloro-N-(pyren-1-ylmethyl)propan-1-amine (1 mmol, 0.3 g), diphenylacetylene (1.5 mmol, 0.27 g), copper acetate (2 mmol, 0.36 g), [Cp*RhCl2]2(5 mol%), sodium tetrafluoroborate (1.5 mmol, 0.165 g), and methanol (5 mL), stirred overnight at 100°C, filtered, and the filtrate was concentrated under reduced pressure. The product was obtained using column chromatography (CH2Cl2:MeOH=5:1) (red solid, yield 81%, 0.458 g).
[0132] 1 H NMR (400 MHz, DMSO) δ 11.33 (s, 1H), 9.66 (d,J= 9.24 Hz, 1H), 9.00 (d,J= 9.16 Hz, 1H), 8.73 (d,J= 7.8 Hz, 1H), 8.58 (d,J= 7.32 Hz, 1H), 8.45 (d,J= 9.2 Hz, 1H), 8.35 (t,J= 7.68 Hz, 1H), 8.26 (d,J= 9.24 Hz, 1H), 8.17 (s, 1H), 7.58 (t,J= 3.52 Hz, 2H), 7.46-7.37 (m, 8H), 4.82 (t,J= 7.4 Hz, 2H), 3.68 (t,J= 6.08 Hz, 2H), 2.44-2.40 (m, 2H); 13C NMR (100 MHz, DMSO) δ 146.6, 143.6, 137.9, 137.8, 135.1, 134.2, 133.6, 131.9, 131.2, 131.0, 130.6, 130.46, 130.40, 129.9, 129.5, 128.8, 128.7, 128.6, 128.5, 128.4, 127.8, 123.5, 122.6, 121.9, 120.8, 120.4, 57.0, 41.9, 33.2; LC / MS(ESI) m / z: 482 [M+H] +
[0133]
[0134] 2. Synthesis example of MF32 (9-(3-chloropropyl)-7,8-bis(4-methoxyphenyl)phenaleno[1,9-gh]isoquinolin-9-ium tetrafluoroborate)
[0135] 3-chloro-N-(pyren-1-ylmethyl)propan-1-amine and 1,2-bis(4-methoxyphenyl)ethyne were obtained using the above MF19 synthesis method (red solid, yield 82%, 0.259 g).
[0136] 1H NMR (400 MHz, CDCl3) δ 11.44 (s, 1H), 9.54 (d,J= 9.0 Hz, 1H), 8.68 (d,J= 8.96 Hz, 1H), 8.47 (d,J= 7.8 Hz, 1H), 8.31 (d,J= 7.32 Hz, 1H), 8.22-8.15 (m, 2H), 8.11 (s, 1H), 7.91 (d,J= 9.12 Hz, 1H), 7.24 (d,J= 8.64 Hz, 2H), 7.15 (d,J= 8.6 Hz, 2H), 6.94 (dd,J= 8.58, 6.96 Hz, 4H), 5.07 (t,J= 7.32 Hz, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 3.61 (t,J= 5.6 Hz, 2H), 2.458-2.453 (m, 2H); 13 C NMR (100 MHz, CDCl3) δ 160.8, 159.7, 147.0, 143.6, 139.1, 139.0, 136.1, 134.1, 132.8, 131.9, 131.86, 131.81, 130.8, 130.7, 129.3, 128.6, 128.2, 127.7, 126.4, 123.6, 123.1, 122.3, 121.7, 120.7, 114.6, 114.3, 57.53, 55.6, 55.5, 41.3, 34.2; LC / MS(ESI) m / z: 542 [M+H] +
[0137]
[0138] 3. Synthesis example of MF33 (9-(3-chloropropyl)-7,8-bis(4-fluorophenyl)phenaleno[1,9-gh]isoquinolin-9-ium tetrafluoroborate)
[0139] 3-chloro-N-(pyren-1-ylmethyl)propan-1-amine and 1,2-bis(4-fluorophenyl)ethyne were obtained using the above MF19 synthesis method (red solid, yield 86%, 0.259 g).
[0140] 1 H NMR (400 MHz, CDCl3) δ 11.64 (s, 1H), 9.63 (d,J= 9.16 Hz, 1H), 8.78 (d,J= 9.04 Hz, 1H), 8.57 (d,J= 7.76 Hz, 1H), 8.39 (d,J= 7.32 Hz, 1H), 8.30 (d,J= 9.08 Hz, 1H), 8.24 (t,J= 7.68 Hz, 1H), 8.05 (s, 1H), 7.97 (d,J= 9.12 Hz, 1H), 7.37-7.34 (m, 2H), 7.24-7.22 (m, 2H), 7.15 (t,J= 8.32 Hz, 4H), 5.10 (t,J= 7.92 Hz, 2H), 3.64 (t,J= 5.56 Hz, 2H), 2.52-2.45 (m, 2H); 13 C NMR (100 MHz, CDCl3) δ 164.5 (d, J C-F = 75.34 Hz), 162.0 (d, J C-F = 72.41), 148.0, 142.5, 139.5, 138.0, 135.6, 134.6, 133.2, 132.7 (d, J C-F = 8.55), 132.4 (d, J C-F = 8.15 Hz), 131.8, 131.0, 130.8, 130.1 (d, J C-F = 3.56 Hz), 129.7, 129.0, 128.5, 127.6, 126.9 (d, J C-F = 3.83 Hz), 124.8, 123.5, 122.4, 121.7, 120.2, 116.7 (d, J C-F = 22.05 Hz), 116.4 (d, J C-F= 21.63 Hz), 57.5, 41.2, 34.2); LC / MS(ESI) m / z: 518 [M+H] +
[0141]
[0142] 4. Synthesis example of MF44 (9-(3-chloropropyl)-7,8-dipropylphenaleno[1,9-gh]isoquinolin-9-ium tetrafluoroborate)
[0143] 3-chloro-N-(pyren-1-ylmethyl)propan-1-amine and 4-octyne were synthesized using the above MF19 method to obtain the product (yellow solid, yield 85%, 41.6 mg).
[0144] 1 H NMR (400 MHz, MeOD) δ 10.79 (s, 1H), 9.36 (d,J= 9.2 Hz, 1H), 8.93 (s, 1H), 8.75 (d,J= 9.12 Hz, 1H), 8.58 (d,J= 7.76 Hz, 1H), 8.46 (d,J= 7.36 Hz, 1H), 8.37 (dd,J= 22.4, 9.16 Hz, 2H), 8.25 (t,J= 7.72 Hz, 1H), 5.13 (t,J= 7.84 Hz, 2H), 3.91 (t,J= 5.84 Hz, 2H), 3.54-3.50 (m, 2H), 3.39-3.37 (m, 2H), 2.71-2.64 (m, 2H), 1.98-1.90 (m, 2H), 1.33-1.29 (m, 6H); 13C NMR (100 MHz, MeOD) δ 146.6, 145.5, 140.3, 138.4, 136.8, 134.8, 133.07, 133.04, 132.4, 131.5, 129.9, 129.8, 129.5, 129.2, 125.5, 124.8, 122.4, 122.2, 120.1, 57.8, 42.5, 35.6, 32.18, 32.15, 25.4, 24.6, 14.9, 14.6; LC / MS(ESI) m / z: 414 [M+H] +
[0145]
[0146] 5. Synthesis example of MF45 (9-(3-chloropropyl)-7,8-bis(4-(dimethylamino)phenyl)phenaleno[1,9-gh]isoquinolin-9-ium tetrafluoroborate)
[0147] 3-chloro-N-(pyren-1-ylmethyl)propan-1-amine and 4,4'-(ethyne-1,2-diyl)bis(N,N-dimethylaniline) were obtained using the above MF19 synthesis method (red solid, yield 75%, 48.9 mg).
[0148] 1H NMR (400 MHz, MeOD) δ 11.01 (s, 1H), 9.49 (d,J= 9.16 Hz, 1H), 8.82 (d,J= 9.12 Hz, 1H), 8.63 (d,J= 7.8 Hz, 1H), 8.46 (d,J= 7.36 Hz, 1H), 8.35-8.26 (m, 3H), 8.06 (d,J= 9.16 HZ, 1H), 7.28 (dd,J= 8.72, 1.96 Hz, 4H), 7.01 (d,J= 8.72 Hz, 2H), 6.80 (d,J= 8.8 Hz, 2H), 4.98 (t,J= 7.52 Hz, 2H), 3.61 (t,J= 5.6 Hz, 2H), 3.09 (s, 6H), 3.01 (s, 6H), 2.46-2.40 (m, 2H); 13 C NMR (100 MHz, MeOD) δ 152.4, 150.3, 146.7, 146.5, 141.0, 140.0, 137.9, 134.9, 133.3, 133.1, 132.8, 132.4, 131.3, 130.0, 129.9, 129.6, 129.0, 125.8, 124.9, 122.7, 122.6, 122.4, 119.8, 115.1, 113.1, 58.9, 42.2, 42.0, 40.5, 34.8; LC / MS(ESI) m / z: 569 [M+H] +
[0149]
[0150] 6. Synthesis example of MF35 (9-(3-chloropropyl)-7,8-bis(4-(diphenylamino)phenyl)phenaleno[1,9-gh]isoquinolin-9-ium tetrafluoroborate)
[0151] 3-chloro-N-(pyren-1-ylmethyl)propan-1-amine and 4,4'-(ethyne-1,2-diyl)bis(N,N-diphenylaniline) were obtained using the above MF19 synthesis method (dark brown solid, yield 77%, 69.6 mg).
[0152] 1 H NMR (400 MHz, MeOD) δ 11.01 (s, 1H), 9.40 (d,J= 9.16 Hz, 1H), 8.75 (d,J= 9.04 Hz, 1H), 8.57 (d,J= 7.8 Hz, 1H), 8.42 (d,J= 7.4 Hz, 1H), 8.40 (s, 1H), 8.32 (d,J= 9.12 Hz, 1H), 8.23 (t,J= 7.68 Hz, 1H), 8.10 (d,J= 9.12 Hz, 1H), 7.35-7.29 (m, 10H), 7.19-7.07 (m, 20H), 5.07 (t,J= 7.64 Hz, 2H), 3.73 (t,J= 5.6 Hz, 2H), 2.54-2.47 (m, 2H); 13 C NMR (100 MHz, MeOD) δ 150.8, 149.7, 148.7, 148.4, 146.8, 145.4, 140.6, 140.0, 137.0, 134.9, 133.25, 133.21, 133.0, 132.8, 132.1, 131.1, 130.77, 130.73, 130.4, 129.9, 129.8, 129.4, 128.9, 128.8, 126.2, 126.0, 125.7, 125.5, 125.3, 125.2, 124.9, 124.5, 123.4, 123.0, 122.6, 122.4, 122.0, 58.7, 42.4, 34.8; LC / MS(ESI) m / z: 817 [M+H] +
[0153]
[0154] In the embodiments of the present invention, in vivo experiments were conducted using 6-week-old male Balb / c athymic nude mice (Orient Bio Inc., Seungnam, Korea) weighing 18 to 20 g, and all animal experimental procedures were maintained and used in accordance with the Animal Care and Use Guidelines of the Laboratory Animal Center of the Daegu-Gyeongbuk Medical Innovation Foundation. Animal experiments were conducted after receiving approval from the Animal Experiment Ethics Review Committee of the Daegu-Gyeongbuk Medical Innovation Foundation (Approval Number: DGMIF-19020701-00).
[0155]
[0156] [Example 1] Fluorescence intensity analysis
[0157] Theranostic agents must have a high signal-to-background ratio. Therefore, in vitro tube imaging was performed to analyze the fluorescence intensity of the compound according to the present invention.
[0158] As shown in FIGS. 1a and 1b, the compounds MF19, MF32, MF33, and MF44 of the present invention exhibited strong fluorescence signals and high absolute quantum yields, while MF35 and MF45 exhibited relatively weak fluorescence signals.
[0159]
[0160] [Example 2] Analysis of cytotoxicity and cancer cell death effects
[0161] To be applied to cancer treatment, theranostic agents must be biocompatible in normal cells but not in cancer cells. Therefore, the compounds of the present invention (MF19, MF32, MF33, and MF44), which exhibited high fluorescence signals, were evaluated for toxicity in normal cells (CHO, L929, CCD-18Co) and colon cancer cells (RKO, SW480, HCT-116) using the CCK-8 assay.
[0162] First, individual cells were seeded in a 96-well plate and treated with different concentrations of synthesized MF33. At the indicated time points, CCK-8 (10 μl / well) reagent was added to the cells, followed by an additional incubation at 37°C for 90 minutes. The absorbance was measured at 450 nm using a plate reader (BioTek instruments, Winooski, USA).
[0163] As shown in Figures 2a to 2d, MF19, MF32, and MF44 exhibited anti-proliferative effects in a concentration-dependent manner in both normal and colon cancer cells. In contrast, MF33 exhibited rapid cytotoxicity in colon cancer cells but not in normal cells, indicating a selective killing effect against cancer cells.
[0164] Accordingly, the effects of MF33 on colony formation ability and apoptosis in HCT-116 cells were further investigated. As shown in Fig. 2f, colony formation ability was decreased in a concentration-dependent manner in HCT-116 cells treated with MF33, but not in HCT-116 cells treated with vehicle. In addition, as shown in Fig. 2g, apoptosis analysis using Annexin V showed that apoptosis was significantly increased by treatment with MF33.
[0165] To determine whether the selective cytotoxicity of MF33 applies to other cancer cell types, we analyzed the effects of MF33 on cell proliferation in lung, prostate, and thyroid cancer cells. As shown in Figure 2e, similar to colorectal cancer cells, MF33 exhibited a dose-dependent antiproliferative effect in A549, PC3, and BHP103scp cells.
[0166]
[0167] [Example 3] Analysis of the mechanism of selective cancer killing
[0168] To analyze the mechanism of selective cancer killing, western blotting analysis was performed using MF33-treated HCT-116 cells.
[0169] First, for total protein extraction, cells were treated with MF33 for 24 h at 37°C in a CO2 incubator and washed twice with phosphate-buffered saline (PBS). Cell pellets were lysed using radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher Scientific, IL, USA) containing a protease and phosphatase inhibitor cocktail kit (Thermo Fisher Scientific). Lysed cells were briefly vortexed at intervals and centrifuged at 13,000 × g at 4°C. Protein samples were quantified using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific).
[0170] Equal amounts of protein were loaded onto a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to a PVDF membrane (Millipore, Billerica, MA, USA). The membrane was blocked with 5% skim milk in Tris-buffered saline (TBS) containing Tween-20 (TBS-T) for 1 h and probed with the respective primary antibodies in 5% BSA overnight at 4°C. After incubation, the membrane was probed with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature. The membrane was washed three times with TBS-T, and the signals were visualized using enhanced chemiluminescence (ECL) detection reagent (GE Healthcare Life Sciences, Pittsburgh, PA, USA).
[0171] The primary antibodies used were as follows: p53 (Santa Cruz, working dilution 1:500), cleaved caspase8 (Cell signaling; dilution 1:1000), cleaved caspase9 (Cell signaling; dilution 1:1000), PARP (Cell signaling; working dilution 1:1000), cleaved caspase3 (Cell signaling; dilution 1:1000). 1:1000), p21 (Cell Signaling; dilution 1:1000), and β-actin (Cell Signaling; dilution 1:5000).
[0172] HRP-conjugated secondary antibodies used were: anti-mouse (Cell Signaling) and anti-rabbit (Cell Signaling).
[0173] Western blotting analysis results (Figs. 3a to 3g) showed that total p53, a tumor suppressor, was upregulated in MF33-treated HCT116 cells, and the expression level of p21, a cell cycle inhibitor, was significantly higher in MF33-treated HCT-116 cells than in vehicle-treated cells. MF33 treatment increased cleaved caspase 8 and caspase 9, which are important effectors in the extrinsic and intrinsic apoptosis pathways, respectively. In addition, cleaved caspase 3 and cleaved PARP were increased in MF33-treated HCT116 cells, suggesting that MF33 induces antiproliferative effects through activation of the p53 / p21 / caspase-3 signaling pathway.
[0174]
[0175] [Example 4] In vivo fluorescence imaging analysis
[0176] In vivo fluorescence imaging was performed after intravenous injection of compound MF33 (1 mg / kg) into nude mice, and images were captured using IVIS Spectrum CT.
[0177] As a result, as shown in Figures 4a and 4b, a strong fluorescent signal of MF33 was detected throughout the mouse's body immediately after injection, and the fluorescent signal decreased over time. Referring to Figures 4c and 4d, a strong fluorescent signal was detected in the resected pancreas and kidney.
[0178]
[0179] [Example 5] Selective cellular uptake analysis in cancer cells
[0180] To analyze whether compound MF33 is selectively uptaken by cancer cells rather than normal cells, normal colon cells (CCD18co) and colorectal cancer cells (RKO and HCT-116) were treated with MF33, and the cellular uptake levels of MF33 were evaluated using flow cytometry.
[0181] As shown in Figures 5a to 5c, little uptake of MF33 was observed in CCD18Co cells at the tested concentrations, whereas colorectal cancer cells showed marked cellular uptake in a concentration-dependent manner.
[0182] Additionally, to analyze whether compound MF33 can visualize tumor lesions in living mice, in vivo fluorescence imaging was analyzed 24 hours after intravenous injection of vehicle or 5 mg / kg MF33 into HCT-116 tumor-bearing mice. As shown in Fig. 5d, fluorescence signals were detected in tumor lesions in mice injected with MF33 but not in those injected with vehicle.
[0183] As shown in Figures 5e and 5f, ex vivo imaging after tumor resection revealed that a bright fluorescent signal was observed in the tumors of MF33-injected mice, but not in vehicle-injected mice.
[0184] From the above results, it can be seen that compound MF33 has selective uptake ability in cancer cells in vivo and in vitro.
[0185]
[0186] [Example 6] Fluorescence signal analysis in sentinel lymph nodes
[0187] Sentinel lymph nodes are a crucial factor in monitoring cancer metastasis. After subcutaneous injection of 1 mg / kg MF33 into the footpad of mice (N=5), lymph nodes were excised 30 minutes later to obtain in vivo fluorescence imaging. As shown in Figures 6a and 6c, a strong fluorescence signal was observed in the MF33-injected foot. As shown in Figure 6b, ex vivo fluorescence imaging also revealed a strong fluorescence signal in the sentinel lymph nodes, while no fluorescence signal was observed in the control lymph nodes. These results indicate that MF33 is also useful for in vivo detection of sentinel lymph nodes.
[0188]
[0189] [Example 7] In vivo antitumor activity analysis
[0190] To analyze the antitumor effect of MF33, HCT-116 tumor-bearing mice were administered 1 mg / kg and 5 mg / kg of MF33 via the intraperitoneal route once a day for 18 days. The vehicle solution was prepared in the ratio of 5% DMSO, 55% DW, and 40% PEG. Tumor size was measured with a caliper and tumor volume (mm 3 ) was calculated using the following formula.
[0191] Tumor volume (mm) 3 ) = d 2 × D / 2
[0192] Where d is the shortest diameter (mm), and D is the longest diameter (mm).
[0193] As a result, vehicle-treated mice exhibited aggressive tumor progression over time (Fig. 7a), whereas MF33 treatment exhibited antitumor activity in a dose-dependent manner (Fig. 7b). Meanwhile, mice treated with 5 mg / kg MF33 exhibited excellent antitumor activity, while mice treated with 1 mg / kg MF33 did not exhibit any antitumor activity.
[0194] As shown in Fig. 7d, tumor weights were lower in MF33-treated mice than in vehicle-treated mice, and a significant difference was also observed in mice treated with 5 mg / kg MF33. During the in vivo antitumor activity assay, no abnormal body weight loss was observed in vehicle-treated or MF33-treated mice (Fig. 7c), confirming the potential of MF33 as a therapeutic agent for colon cancer.
[0195]
[0196] In summary, the above results confirmed that phenaleno isoquinolinium derivative compounds can be used as imaging probes for tumor and sentinel lymph node detection and as selective anticancer agents.
[0197]
[0198] The above description is merely illustrative of the present invention, and those skilled in the art will appreciate that various modifications may be made without departing from the essential characteristics of the present invention. Therefore, the embodiments disclosed in this specification are intended to illustrate, not limit, the present invention, and the spirit and scope of the present invention are not limited by these embodiments. The scope of protection of the present invention should be interpreted by the following claims, and all techniques within a scope equivalent thereto should be interpreted as being included within the scope of the present invention.
[0199] The compound according to the present invention can be used as a cancer diagnostic and therapeutic agent.
Claims
1. A composition for preventing or treating cancer comprising a compound represented by the following chemical formula 1 as an active ingredient. Chemical Formula 1 {In the above chemical formula 1, R 1 Silver substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C7~C 20 is selected from the group consisting of arylalkyl groups; R 2 are each identical, substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C2~C 20 is selected from the group consisting of heterocyclic groups; X - is an inorganic acid ion, an organic acid ion, or a halide, Here, the alkyl group, alkenyl group, arylalkyl group, aryl group and heterocyclic group are deuterium; halogen; C1~C 10 Alkyl group of; C1~C 10 Alkoxy group of; C6~C 20 aryl group of; and -NR'R"; may be further substituted with one or more substituents selected from the group consisting of The above R' and R" are independently C1~C 10 is selected from the group consisting of an alkyl group; a phenyl group; and a halogenated phenyl group.
2. In the first paragraph, the R 1 C1~C substituted with silver halogen 20 Composition for preventing or treating cancer characterized by an alkyl group of 3. In the first paragraph, the R 2 A composition for preventing or treating cancer, characterized in that it is a substituted or unsubstituted phenyl group.
4. In the first paragraph, the R 2 is C1~C 20 Composition for preventing or treating cancer characterized by an alkyl group of 5. In the first paragraph, the R 2 is substituted or unsubstituted C2~C 20 A composition for preventing or treating cancer characterized by a heterocyclic group 6. In the third paragraph, the R 2 A composition for preventing or treating cancer characterized by having a phenyl group 7. In the third paragraph, the R 2 A composition for preventing or treating cancer, characterized in that it is a phenyl group substituted with one or more substituents selected from the group consisting of halogen, C1~C6 alkoxy group and -NR'R", and wherein R' and R" are independently a C1~C6 alkyl group or a phenyl group.
8. In paragraph 1, the cancer is brain cancer, neuroendocrine cancer, myeloma, lymphoma, leukemia, lymphangioendotheliosarcoma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, glioma, meningioma, neuroblastoma, EMC (extraskeletal myxoid chondrosarcoma), gastric cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, adrenal cancer, colon cancer, colon cancer, cervical cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, parathyroid cancer, ureteral cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, colon adenocarcinoma, prostate carcinoma, squamous cell carcinoma, basal cell carcinoma, A composition for preventing or treating cancer, characterized by comprising adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma, biliary tract cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, hemangiosarcoma, endotheliosarcoma, lymphangiosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, rhabdomyosarcoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, bulbar thyroid carcinoma, bronchial carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, Kaposi's sarcoma, or retinoblastoma.
9. In claim 1, the composition is a composition for preventing or treating cancer characterized in that it induces rapid apoptosis of cancer cells through the p53, p21 or caspase-3 signaling pathway.
10. A composition for near-infrared treatment of cancer comprising a compound represented by the following chemical formula 1 as an active ingredient. Chemical Formula 1 {In the above chemical formula 1, R 1 Silver substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C7~C 20 is selected from the group consisting of arylalkyl groups; R 2 are each identical, substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C2~C 20 is selected from the group consisting of heterocyclic groups; X - is an inorganic acid ion, an organic acid ion, or a halide, Here, the alkyl group, alkenyl group, arylalkyl group, aryl group and heterocyclic group are deuterium; halogen; C1~C 10 Alkyl group of; C1~C 10 Alkoxy group of; C6~C 20 aryl group of; and -NR'R"; may be further substituted with one or more substituents selected from the group consisting of The above R' and R" are independently C1~C 10 is selected from the group consisting of an alkyl group; a phenyl group; and a halogenated phenyl group.
11. A composition for preventing or treating cancer metastasis, comprising a compound represented by the following chemical formula 1 as an active ingredient. Chemical Formula 1 {In the above chemical formula 1, R 1 Silver substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C7~C 20 is selected from the group consisting of arylalkyl groups; R 2 are each identical, substituted or unsubstituted C1~C 20 Alkyl group of; substituted or unsubstituted C2~C 20 Alkenyl group of; substituted or unsubstituted C6~C 20 Aryl group of; and substituted or unsubstituted C2~C 20 is selected from the group consisting of heterocyclic groups; X - is an inorganic acid ion, an organic acid ion, or a halide, Here, the alkyl group, alkenyl group, arylalkyl group, aryl group and heterocyclic group are deuterium; halogen; C1~C 10 Alkyl group of; C1~C 10 Alkoxy group of; C6~C 20 aryl group of; and -NR'R"; may be further substituted with one or more substituents selected from the group consisting of The above R' and R" are independently C1~C 10 is selected from the group consisting of an alkyl group; a phenyl group; and a halogenated phenyl group.
12. A method for treating cancer in a non-human animal, comprising administering a composition according to any one of claims 1 to 11.
Citation Information
Patent Citations
Transition metal-phthalocyanine polymer and coating method of current collector using the polymer
KR1020240130543A
